Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease

被引:599
|
作者
Adlard, PA [1 ]
Perreau, VM [1 ]
Pop, V [1 ]
Cotman, CW [1 ]
机构
[1] Univ Calif Irvine, Inst Brain Aging & Dementia, Irvine, CA 92697 USA
来源
JOURNAL OF NEUROSCIENCE | 2005年 / 25卷 / 17期
关键词
Alzheimer's disease; exercise; amyloid; transgenic; APP; TgCRND8;
D O I
10.1523/JNEUROSCI.0496-05.2005
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Alzheimer's disease ( AD) is a progressive neurodegenerative disorder for which there are few therapeutics that affect the underlying disease mechanism. Recent epidemiological studies, however, suggest that lifestyle changes may slow the onset/progression of AD. Here we have used TgCRND8 mice to examine directly the interaction between exercise and the AD cascade. Five months of voluntary exercise resulted in a decrease in extracellular amyloid-beta (A beta) plaques in the frontal cortex (38%; p = 0.018), the cortex at the level of the hippocampus (53%; p = 0.0003), and the hippocampus (40%; p = 0.06). This was associated with decreased cortical A beta 1 - 40 (35%; p = 0.005) and A beta 1 - 42 (22%; p = 0.04) (ELISA). The mechanism appears to be mediated by a change in the processing of the amyloid precursor protein (APP) after short-term exercise, because 1 month of activity decreased the proteolytic fragments of APP [ for alpha-C-terminal fragment (alpha-CTF), 54% and p = 0.04; for beta-CTF, 35% and p = 0.03]. This effect was independent of mRNA/protein changes in neprilysin and insulin-degrading enzyme and, instead, may involve neuronal metabolism changes that are known to affect APP processing and to be regulated by exercise. Long-term exercise also enhanced the rate of learning of TgCRND8 animals in the Morris water maze, with significant ( p < 0.02) reductions in escape latencies over the first 3 ( of 6) trial days. In support of existing epidemiological studies, this investigation demonstrates that exercise is a simple behavioral intervention sufficient to inhibit the normal progression of AD-like neuropathology in the TgCRND8 mouse model.
引用
收藏
页码:4217 / 4221
页数:5
相关论文
共 50 条
  • [31] Ultrastructural and behavioural changes precede amyloid deposition in a transgenic model of Alzheimer's disease
    Richardson, JC
    Kendal, CE
    Anderson, R
    Priest, F
    Gower, E
    Soden, P
    Gray, R
    Topps, S
    Howlett, DR
    Lavender, D
    Clarke, NJ
    Barnes, JC
    Haworth, R
    Stewart, MG
    Rupniak, HTR
    NEUROSCIENCE, 2003, 122 (01) : 213 - 228
  • [32] Genetic modifiers of amyloid-β production in a transgenic mouse model of Alzheimer's disease
    Ryman, DC
    Lamb, BT
    NEUROLOGY, 2006, 66 (05) : A379 - A379
  • [33] Peripheral neprilysin reduces brain amyloid in a transgenic mouse model of Alzheimer's disease
    Liu, Y. X.
    Guan, H. J.
    Klein, R.
    Oddo, S.
    LaFerla, F. M.
    Murphy, M. P.
    Hersh, L. B.
    JOURNAL OF NEUROCHEMISTRY, 2009, 109 : 300 - 300
  • [34] Hypercholesterolemia accelerates amyloid pathology in a transgenic mouse model of Alzheimer's disease.
    Refolo, L
    Duff, K
    Malester, B
    LaFrancois, J
    Wang, R
    Sambamurti, K
    Tint, GS
    Thomas, T
    Pappolla, MA
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2000, 59 (05): : 424 - 424
  • [35] Fibrillar β-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease
    Matsuoka, Y
    Picciano, M
    La Francois, J
    Duff, K
    NEUROSCIENCE, 2001, 104 (03) : 609 - 613
  • [36] Testing the amyloid toxicity hypothesis of Alzheimer's disease in transgenic Caenorhabditis elegans model
    Gutierrez-Zepeda, A
    Luo, Y
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2004, 9 : 3333 - 3338
  • [37] Mitochondrial dysfunction in amyloid precursor protein transgenic mouse model of Alzheimer's disease
    Scherping, I
    Czech, C
    Pradier, L
    Müller, WE
    Eckert, A
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2004, 369 : R15 - R15
  • [38] Cerebrolysin™ protects against cerebrovascular amyloid angiopathy in a transgenic model of Alzheimer's disease
    Rockenstein, E
    Adame, A
    Mante, M
    Moessler, H
    Windisch, M
    Masliah, E
    NEUROBIOLOGY OF AGING, 2004, 25 : S587 - S587
  • [39] Blocking the chaperoning effect of apolipoprotein E reduces β-amyloid load in Alzheimer's disease transgenic mice
    Sadowski, M
    Pankiewicz, J
    Scholtzova, H
    Ripellino, JA
    Schmidt, SD
    Mathews, PW
    Sigurdsson, EM
    Wisniewski, T
    NEUROLOGY, 2004, 62 (07) : A522 - A522
  • [40] Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease
    Weiner, HL
    Lemere, CA
    Maron, R
    Spooner, ET
    Grenfell, TJ
    Mori, C
    Issazdeh, S
    Hancock, WW
    Selkoe, DJ
    ANNALS OF NEUROLOGY, 2000, 48 (04) : 567 - 579